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Checkpoint molecules such as programmed death 1 (PD-1) dampen excessive T cell activation to 
preserve immune homeostasis. PD-1-specific monoclonal antibodies have revolutionized cancer 
therapy, as they reverse tumour-induced T cell exhaustion and restore CTL activity. Based on this 
success, deciphering underlying mechanisms of PD-1-mediated immune functions has become an 
important field of immunological research. Initially described for T cells, there is emerging evidence 
of unconventional PD-1 expression by myeloid as well as tumor cells, yet, with cell-intrinsic functions 
in various animal tumor models. Here, we describe positive PD-1 antibody staining of various murine 
immune and tumour cells that is, unlike for T cells, not the PD-1 receptor and restricted to cells with 
low forward scatter characteristics. Based on flow cytometry and various approaches, including two 
established murine anti-PD-1 antibody clones, CRISPR/Cas9 genome editing and confocal imaging, 
we describe a staining pattern assigned to a nuclear antigen cross-reacting with anti-PD-1 monoclonal 
antibodies. Lack of PD-1 expression was further underlined by the analysis of PD-1 expression from 
B16-F10-derived 3D cultures and ex vivo tumours. Thus, our data provide multiple lines of evidence that 
PD-1 expression by non-T cells is unlikely to be the case and, taking recent data of PD-1 tumour cell-
intrinsic functions into account, suggest that other antibody-mediated pathways might apply.
The quality of innate and adaptive immune cell activation pathways underlies a sensitive balance that is, at least 
in parts, regulated by immune checkpoints to maintain immune homeostasis1. Checkpoint blockade has substan-
tially improved the therapy of several cancer types including melanoma2, non-small cell lung cancer3,4 as well as 
head and neck squamous cell carcinoma5, and holds promise for a variety of mismatch repair-deficient tumours, 
for example those found in colorectal cancer6. Within immune checkpoints discovered today, programmed cell 
death 1 (PD-1) is one of the best-characterized molecules and the therapeutic application is based on the role of 
PD-1 in regulation of T cell function, as it alters metabolic and cell cycle processes7. Under physiological condi-
tions, PD-1 dampens immune responses by inhibiting T cell activation, otherwise leading to immune-mediated 
pathologies8.
The redundancy of inhibitory pathways is also hijacked by tumours to cause T cell exhaustion, which then 
results in tumour immune evasion. While the ligand for PD-1 receptor, PD-L1, is expressed on various immune 
and non-immune cells including tumour cells, PD-1 receptor expression and function have recently been shown 
not only for T cells, but also for B cells and other cells of the innate immune system9–12. Even more surprising, a 
recent report described PD-1 expression in a subset of murine melanoma cells, which promoted tumour growth 
in a cell-intrinsic manner. This non-canonical concept, however, clearly challenges the cancer immunology field 
to revisit the general concept of anti-PD-1-directed therapies, initially assumed to exclusively target T cells in 
tumour bearing hosts13.
Unexpected PD-1 expression on cells other than T cells is quite intriguing and greatly enhances the field 
of immunological research, with potential implications in tumor therapy. Hence, recent advances in this field 
warrant further clarification and prompted us to investigate PD-1 expression on several murine immune and 
non-immune cells, including various tumour models. However, there is a thin line between carefully controlled 
experimental procedures and data interpretation, where recent study designs rather fell short. A major hurdle 
involved in the experimental design ist the choice of validated and reliable key resources of tools that allow 
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retrospective data analysis and conclusions. Thus, poor reproducibility of published results is still a critical issue, 
which is mostly based on a insufficiently-described methodology or questionable antibodies. Antibodies are the 
backbone of protein science, however, earlier studies have revealed that less than 50% actually suffuciently meet 
desired quality requirements14. With this is mind, we aimed at validating two widely-used murine anti-PD-1 
antibody clones, 29 F.1A12 and RMP1-14, which are known to target PD-1 and block binding to its ligand 
PD-L1. Based on flow cytometry, we compared PD-1 expression of various immune and non-immune cells to the 
canonical PD-1 expression profile of T cells. By employing tightly controlled FACS- and image-based validation 
approaches in wild-type and PD-1-deficient cells, we identified a cross-reactive nuclear antigen that becomes 
available in dead or dying cells. In summary, we confirmed PD-1 staining of T cells for both antibody clones used; 
however, applying well-controlled gating strategies, tumour cells and other immune cellswere found negative for 
PD-1 expression, thus, challenging interpretation of recently published animal models.
Results and Discussion
Expression of PD-1 by immune cells populations in spleens of tumour-bearing mice. Amongst 
the plethora of suppressive mechanisms, the PD-1/PD-L1 axis represents one of the most potent inhibitory sig-
nalling cascades to abort T cell-mediated tumour killing. Tumour-derived factors lead to an upregulation of 
PD-1 expression in tumour-infiltrating T cells and potentially other immune cell types, such as B cells and innate 
immune cells9–11,15,16. To study PD-1 expression by immune cell subsets in tumour bearing hosts, mice were 
challenged with a GEMM-derived orthotopic pancreatic tumour17 and splenic immune cell populations were 
assessed by flow cytometry. The gating strategy included live cell and singlet gates, combined with CD45 to iden-
tify immune cells. We added FcRII/FcRIII blocking antibodies prior staining for CD3, CD4, CD8 and CD19 to 
investigate T and B cells (I and II). In addition, we added a third gate (III) to include remaining cells of the innate 
immune system (Fig. 1). PD-1 was expressed by CD4+ and CD8+ T cells (Fig. 1, gate I). In addition, PD-1 staining 
(clone 29F1A12) uncovered a FSC-Hlow population predominantly positive for PD-1. As we routinely included 
the fixable viability dye (FVD) for dead cell exclusion, we observed that the FSC-Hlow PD-1+ population mainly 
contained dead cells. In addition, PD-1 expression has been also shown for B cells as well as other innate immune 
cells under malignant, infectious or autoinflammatory conditions9–11,15,16. Following the same gating strategy, 
we observed a similar FSC-Hlow staining pattern in B cells and innate immune cells; however, FVD staining 
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Figure 1. Expression of PD-1 by immune cell populations in spleens of tumour-bearing mice. Spleens of 
mice with orthotopic pancreatic tumours were removed to assess immune cell populations by flow cytometry. 
Live cell (FCS-A/SSC) and singlet (FSC-A/FSC-H) cell gating was done. Anti-CD45 antibody was applied for 
assessing immune cell populations, which were subdivided into CD3+CD4+ as well as CD3+CD8+ T cells (gate 
I), CD19+ B cells (gate II) and CD3-CD19- innate immune cells (gate III). PD-1 (clone 29F.1A12) and fixable 
viability dye (FVD) staining was assessed by flow cytometry. Gates I – III show PD-1/FSC-H and PD-1/fixable 
viability dye (FVD) staining of respective cell populations. One out of three independent experiments is shown.
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confirmed PD-1 staining only for dead cells (Fig. 1, gate II and III). Based on this data, PD-1 expression was 
limited to T cells in this tumour model.
PD-1-specific mAb recognize an antigen exposed by dead cells. A decrease in the forward scatter 
(FSC-Hlow) of PD-1+ populations indicates alterations in cellular volume, as observed in dying cells. PD-1 stain-
ing (clone 29 F.1A12) in these cells could be due to binding of an intracellular PD-1 pool that becomes accessi-
ble in cells with leaky membranes. On the other hand, off-target binding of the antibody can either occur via 
ionic or hydrophobic interactions or stickiness of dying cells that release high amounts of DNA18,19. To address 
this question, we analysed PD-1 expression in primary CD4+ T cells from wild-type and Pdcd1−/− mice. As 
expected, wild-type CD4+ T cells, but not PD-1−/− T cells, expressed PD-1. This observation became even more 
pronounced after T cell activation with anti-CD3/anti-CD28 beads, clearly demonstrating the specificity of the 
anti-PD-1 mAb within viable (FVD−) cells (Fig. 2a). Interestingly, we detected PD-1/FVD double-positive cells 
in wild-type as well as in PD-1−/− cells. Thus, PD-1 staining in the dead cell fraction is due to cross-reactivity. To 
confirm these data in a second model, we performed CRISPR/Cas9-targeted PD-1 deletion in the B3Z hybrid-
oma T cell line. B3Z T cells (B3Z-sgScr) intrinsically express high PD-1 levels, which was absent in PD-1-deleted 
(B3Z-sgPdcd1) cells (Fig. 2b). Again, PD-1 mAb staining (clone 29 F.1A12) was found in both PD-1 wild-type 
and knock-out cells in the dead cell fraction, indicative of unspecific binding. This became even more evident 
when cells were treated with the apoptosis inducer staurosporine (Fig. 2b). Our data clearly underline the neces-
sity of a strict gating strategy to rule out false positive findings induced by dying or dead cells.
B16-F10 melanoma cells do not express PD-1. A recent publication attracted our attention showing 
B16 melanoma-intrinsic PD-1 receptor functions supporting tumour growth13. The authors claim dead cell exclu-
sion; however, the PD-1+ subpopulation of B16-F10 melanoma cells shown in this work exhibits FSC-Hlow prop-
erties, as compared to the main PD-1− cell population. Thus, we were interested in PD-1 expression of B16-F10 
cells and first assessed mRNA expression levels by RT-PCR. B3Z cells served as positive control, expressing 
high PD-1 mRNA levels. In contrast, we could not detect PD-1 mRNA in B16-F10 cells. To confirm our data and 
to rule out sensitivity limitations, we additionally performed CRISPR/Cas9-targeted gene knockout in B16-F10 
melanoma cells. PD-1 knockout single cell clones were validated by Sanger sequencing of individual alleles 
(Supplementary Fig. S1a). We assessed PD-1 expression by flow cytometry and compared the two mainly used 
antibody clones (29 F.1A12 and RMP1-14), which were also included in the above-mentioned study. We found a 
fraction of approximately 2–5% PD-1+ tumour cells with FSC-Hlow properties, quite similar to published results13 
(Fig. 3b). This staining pattern was seen in control and PD-1 knock-out tumour cells, indicative of unspecific 
binding. To demonstrate that the FSC-Hlow population contained dead cells, we co-stained cells with fixable 
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Figure 2. PD-1-specific mAb recognize an antigen exposed by dead cells. (a) Wild-type or Pdcd1−/− mice were 
stimulated with anti-CD3/anti-CD28 beads for 48 h or left untreated. Anti-PD-1 (clone 29 F.1A12) and fixable 
viability dye (FVD) staining of CD4+ T cells was assessed by flow cytometry. (b) The B3Z hybridoma T cell line 
was targeted with CRISPR/Cas9, by using a scrambled (B3ZsgScr) or a PD-1-directed (B3ZsgPdcd1) sgRNA, 
and treated with staurosporine (1 µM) or left untreated. PD-1 as well as FVD staining was studied by flow 
cytometry. One out of three independent experiments is shown.
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viability dye (FVD). We observed PD-1 staining exclusively in the dead cell fraction for both clones 29 F.1A12 
and RMP1-14 mAb, respectively. Again, this staining pattern became more evident by staurosporine treatment of 
the tumour cells (Fig. 3b and Supplementary Fig. S1b). The results were also confirmed by other cell death mark-
ers, such as 7-AAD and propidium iodide (Supplementary Fig. S1c). Of note, PD-1 staining of dead cells was not 
limited to the B16-F10 melanoma cell line, but also observed for other tumour entities, including hepatocellular 
carcinoma and pancreatic cancer cell lines (Supplementary Fig. S2).
Next, we investigated binding of PD-1 to its natural ligand by using recombinant Fc-tagged PD-L1. Binding 
was only observed in the B3Z wild-type cell line, but not in PD-1-deficient B3Z or wild-type B16-F10 tumour 
cells, providing further evidence for the lack of PD-1 expression in B16-F10 cells (Fig. 3c). It is conceivable that 
variations in cell culture conditions lead to altered gene expression, an exciting approach in cancer stem cell 
(CSC) research13,20, which has been applied for B16 melanoma cells by using different geometric culture shapes21. 
Here, the authors found the CSC-related marker ABCB5 and correlated it to the expression of costimulatory 
B7.2 and PD-1 in established melanoma22. We made use of an in vitro ‘hanging drop’ culture system to grow 
B16-F10 cells as three-dimensional spheres (Supplementary Fig. S3a). Furthermore, we analysed PD-1 expres-
sion of freshly-isolated B16-F10 tumour cells (Supplementary Fig. S3b). Again, we were unable to detect PD-1 
expression in viable tumour cells for all approaches tested, including two- and three-dimensional culture methods 
as well as in vivo conditions.
Anti-PD-1 mAb is cross-reactive with a nuclear antigen. Isotype-controlled PD-1 staining of FVD+ 
cells suggests cross-reactivity of anti-PD-1 mAb with an antigen accessible in dead cells. Indeed, intracellular 
staining (clone 29 F.1A12) of both wild-type and PD-1−/− B16-F10 cells revealed staining in nearly all B16-F10 
control (B16sgScr) and PD-1−/− (B16sgPdcd1) melanoma cells, as assessed by flow cytometry (Fig. 4a). To 
address the question of the subcellular localization, we performed confocal microscopy comparing B3Z cells with 
untreated and staurosporine-treated B16-F10 melanoma cells. As expected, untreated B3Z cells showed strong 
plasma membrane-associated PD-1 staining (clone 29 F.1A12), which was absent in B16-F10 cells. Staurosporine 
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Figure 3. B16-F10 melanoma cells do not express PD-1. (a) PD-1 mRNA expression of B3Z and B16-F10 
melanoma cells was assessed by qRT-PCR. Cropped blots show qRT-PCR transcripts using 3% agarose gel 
electrophoresis (for full blot, see Supplementary Figure S4). (b) CRISPR/Cas9-targeted B16-F10 control 
(B16sgScr) and PD-1−/− (B16sgPdcd1) cells were cultured in the absence or presence of staurosporine (1 µM). 
Anti-PD-1 antibody (clone 29 F.1A12) and fixable viability dye (FVD) staining was analysed by flow cytometry. 
(c) B3Z control (B3ZsgScr) and PD-1−/− (B3ZsgPdcd1) as well as B16-F10 control (B16sgScr) and PD-1−/− 
(B16sgPdcd1) cells were treated with staurosporine (B16-F10) or left untreated (B3Z and B16-F10). Cells were 
stained with recombinant mouse PD-L1-Fc fusion protein and FVD. One out of three independent experiments 
is shown.
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treatment unravelled a significant proportion of B16-F10 cells that stained positive with the anti-PD-1 antibody. 
This was independent of PD-1-expression and was strictly located within the nucleus (Fig. 4b). Of note, sparse 
cells within untreated PD-1−/− B16-F10 cells also showed the nuclear staining pattern, indicative of spontaneous 
cell death with antibody passage via leaky membranes.
From our experiments we conclude that B16-F10 melanoma cells and other tumour cell lines do not express 
PD-1. In fact, PD-1 staining of tumour cells is due to cross-reactivity of anti-PD-1 mAb with a nuclear antigen 
that only becomes accessible in dying cells, possibly through leaky membranes. Here, our data clearly shows that 
the concept of PD-1 expression on tumour cells, including cell-intrinsic downstream effects, has to be challenged. 
In addition, the comprehensive approach of validated antibody sources should be enhanced by careful gating 
strategies, which is accompanied by dead cell exclusion, and routinely used when studying PD-1 expression in T 
cells and other cell types. Antibodies are the supporting pillar in biological sciences and pivotal to pave the road 
from bench to bed-side, starting development in animal models. At the point where we tested two major murine 
antibody clones for their PD-1 specificity it is important to state that another recently used goat anti-mouse PD-1 
antibody was already discontinued, thus, evading our validation efforts. Thus, further investigations are necessary 
to revisit the basic immunological concept with possible antibody-mediated implications, when working with 
anti-PD-1 antibodies in animal models.
Material and Methods
Mice, tumour induction and cell isolation. C57BL/6 J mice were purchased from Janvier Labs (Le 
Genest-Saint-Isle, France) and Pdcd1 knockout mice were a kind gift from Prof. Protzer (Institute of Virology, 
Technical University of Munich, Germany). Experimental animal procedures conformed to the guidelines 
and regulations of the Animal Care Committee and were approved by the local government (Regierung von 
Oberbayern, Maximilianstrasse 39, 80538 Munich; GZ 55.2-1-54-2532-175-2012). For tumour induction, 2 × 105 
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Figure 4. PD-1 mAb is cross-reactive with a nuclear antigen. (a) CRISPR/Cas9-targeted B16-F10 control 
(B16sgScr) and PD-1−/− (B16sgPdcd1) cells were stained with FVD, permeabilized, stained with anti-PD-1 
antibody (clone 29 F.1A12) and analysed by flow cytometry. (b) B16-F10 control (B16sgScr) cells as well as B3Z 
cells were treated with staurosporine or left untreated prior to anti-PD-1 antibody staining (clone 29 F.1A12) 
(red). Nuclei were counterstained with Hoechst 33342 (blue). Localization of anti-PD-1 staining pattern was 
analysed by confocal microscopy. Representative data of two independent experiments are shown.
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T110299 cells were orthotopically implanted into the pancreas of C57BL/6 J mice. After 21 days, mice were sacri-
ficed and spleens were removed for cell isolation. Spleens were meshed and passed through a 70 µm cell strainer 
(Miltenyi SmartStrainer, Miltenyi, Bergisch Gladbach, Germany) to obtain a single cell suspension. Red blood cell 
lysis (BD Pharm Lyse™, BD Biosciences, Heidelberg, Germany) was done prior antibody staining for flow cyto-
metric analysis. For the B16-F10 tumour model, 1 × 105 cells were injected s.c. into the flanks of C57BL/6 mice. 19 
days after engraftment, tumours were removed and processed into single cell suspensions using collagenase and 
DNase (Sigma-Aldrich, Munich, Germany) at 37 °C for 30 minutes. Tumour cells were filtered through a 100 µm 
mesh, washed and stained for flow cytometer analysis.
Cell culture and reagents. B16-F10 (ATCC; RRID:CVCL_0159), Hep-55.1 C (CLS; RRID: CVCL_5766), 
Hepa1-6 (ATCC; RRID: CVCL_0327), RIL175 (Prof. Greten), Pan02 (Prof. Lauber) and T110299 (Prof. Siveke; 
Ptf1a-Cre LSL-KrasG12D LSL-Trp53fl/R172H) cells were cultured in DMEM (Lonza, Cologne, Germany) supple-
mented with 10% fetal calf serum (FCS; ThermoFisher Scientific, Darmstadt, Germany), 2 mM L-glutamine 
(Lonza, Cologne, Germany) and 10 µg/ml ciprofloxacin (Fresenius Kabi, Bad Homburg, Germany). B3Z T cell 
hybridoma cells were cultured in RPMI 1640 (Lonza, Cologne, Germany) supplemented with 10% FCS, 2 mM 
L-glutamine and 10 µg/ml ciprofloxacin. Splenocytes were cultured in RPMI 1640 supplemented with 10% FCS, 
2 mM L-glutamine, 100 U/L penicillin, 0.1 mg/ml streptomycin (all Lonza, Cologne, Germany), 1 mM sodium 
pyruvate (Biochrom, Berlin, Germany) and 0.1 mM non-essential amino acids (ThermoFisher, Darmstadt, 
Germany). For T cell activation, cells were seeded at 1 × 106 cells/0.5 ml in a 48-well plate, in the presence or 
absence of anti-CD3/anti-CD28 Dynabeads® (ThermoFisher, Darmstadt, Germany). Cells remained in culture 
for 48 h and were subsequently processed for flow cytometry. For cell death induction, cells were treated with 
1 µM staurosporine (Sigma Aldrich, Munich, Germany) for 4–6 hours.
Generation of PD-1 knockout cell lines. PD-1 knockout cells were generated using a lentiviral CRISPR/
Cas9 method as described23,24. In brief, sgRNA sequences were obtained from GeCKOv2 mouse library. DNA 
oligonucleotides encoding for the sgRNA sequences and a BsmBI restriction overhang were cloned into a pLen-
tiCRISPRv2_ccdB_Cas9-P2A-Puro vector (a gift from Marc Schmidt-Supprian, TU Munich). HEK 293 T cell 
were transfected with the sgRNA encoding pLentiCRISPRv2 vector, pcMV_dR8-74 and pVSVG (Addgene). 
After 48 hours, lentivirus-containing supernatant was transferred to target cells (B16-F10 and B3Z). After fur-
ther 48 hours, transduced cells were treated with puromycin for positive selection. PD-1 negative B3Z cells 
were single-cell sorted into a 96-well plate using BD FACSAriaTM III cell sorter (BD Biosciences, Heidelberg, 
Germany). Single-cell clones of B16-F10 cells were obtained by serial dilution. For verification of PD-1 knock-
out, genomic DNA was isolated using the QuickExtract™ DNA Extraction Kit (Epicentre, Madison, WI, USA). 
After target amplification, genomic editing was verified by T7 endonuclease digest as described25. For B16F10 
cells, individual alleles were cloned into a plasmid and sequenced by Sanger sequencing (Eurofins Genomics, 
Ebersberg, Germany).
FACS analysis. Single cell suspensions were incubated with anti-PD-1 mAb (1:200 dilution; clones 29 F.1A12 
or RMP1-14; both BioLegend, London, UK) in PBS containing FCS (1%) and EDTA (2 mM) (staining buffer) for 
30 min on ice. Dead cell staining was included as indicated, using eFluor 780-conjugated fixable viability (FVD; 
1:5000; ThermoFisher, Darmstadt, Germany), propidium iodide (1 µg/ml; Sigma-Aldrich, Munich, Germany) 
or 7-AAD (2.5 µg/ml; ThermoFisher, Darmstadt, Germany). Intracellular staining was done using the Foxp3/
Transcription Factor Staining Buffer Set according to the manufactures One-step protocol (ThermoFisher, 
Darmstadt, Germany). In brief, following dead cell staining with the FVD, cells were fixed, permeabilized and 
subsequently stained with the anti-PD-1 antibody. Samples were analysed with the BD FACSCantoTM II and BD 
LSRFortessaTM flow cytometer (BD Biosciences, Heidelberg, Germany).
qRT-PCR. B3Z and B16-F10 total RNA was isolated with the peqGOLD Total RNA Kit (VWR International, 
Darmstadt, Germany) and adjusted RNA was transcribed into cDNA using the RevertAid First Strand cDNA 
Synthesis Kit (ThermoFisher, Darmstadt, Germany), according to the manufacturers’ protocol. qRT-PCR was 
done with the Kapa Probes Fast Universal Kit (Kapa Biosystems, Roche, Penzberg, Germany) on a LightCycler® 
480 II instrument (Roche, Penzberg, Germany), using the Roche Universal Probes library for the primer design 
of β-actin and PD-1. For visualization of mRNA transcripts, qRT-PCR samples were loaded onto a 3% agarose 
gel (Tris-acetate-EDTA buffer) and stained with SERVA DNA Stain Clear G (Serva Electrophoresis GmbH, 
Heidelberg, Germany). Images were acquired using the AlphaImager® with the AlphaEase® FC Software v6 
(Alpha Innotech, Kasendorf, Germany).
‘Hanging drop’ 3D culture. 1 × 102 B16-F10 cells were seeded on the lid of a non-adherent plate in 50 µl 
culture medium. After seeding, the lid was turned upside down. Cells were cultured for up to 10 days in a humid-
ified incubator at 37 °C with 5% CO2.
Confocal microscopy. Glass slides (ThermoFisher, Darmstadt, Germany) were treated overnight with 
1 M HCl, washed with PBS and 1 × 105 cells were seeded onto the pre-treated glass dishes. Cells were incubated 
with PE-conjugated rat anti-PD-1 primary antibody (1:200; clone 29 F.1A12; BioLegend) in staining buffer for 
30 min on ice. After washing in staining buffer, secondary staining was done with AF647-coupled anti-rat IgG 
(ThermoFisher, Darmstadt, Germany) antibody for 30 min on ice. Subsequently, cells were washed in staining 
buffer containing Hoechst 33342 solution (1:5000; ThermoFisher, Darmstadt, Germany), and visualized with a 
Leica SP5 II confocal microscope (Leica, Wetzlar, Germany).
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Data availability. All data generated or analysed during this study are included in this published article and 
its supplementary information files.
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